BPC-157 + TB-500 + GHK-Cu + KPV Stack
Multi-peptide combination stack for tissue repair, inflammation modulation, and regenerative support
- Class
- 4-peptide stack
- Half-life
- Variable
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Weak / anecdotal
Overview
This is a four-peptide combination stack that pairs BPC-157 and TB-500 (the core 'Wolverine stack' for tissue repair) with GHK-Cu (a copper peptide for collagen synthesis and skin health) and KPV (an anti-inflammatory tripeptide). Sold under names like KLOW Stack or Hyper Recovery Stack, it's marketed as a comprehensive healing protocol that hits every phase of tissue repair — from inflammation control through to collagen remodeling.
The rationale is mechanistic: BPC-157 drives local angiogenesis and tissue signaling, TB-500 promotes systemic cell migration, KPV suppresses NF-κB inflammatory signaling, and GHK-Cu stimulates collagen production and extracellular matrix remodeling. Each component targets a different bottleneck in the healing cascade, so in theory they should complement rather than overlap.
The catch: there are zero human trials on this specific four-peptide combination, and zero animal studies testing all four together in the same experiment. Every protocol you'll find is practitioner-derived or community-sourced, built on mechanistic theory rather than controlled data. Each individual peptide has its own evidence base (thin to moderate, mostly animal), but the stack itself is untested. You're combining four research peptides, each with its own safety unknowns, and multiplying the variables.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use by FDA, EMA, or any regulator. Each component is a research chemical; the combination is entirely unregulated.
- Zero human safety data on this specific 4-peptide combination. You're combining four peptides with their own thin safety profiles — interaction risks are completely unknown.
- BPC-157, TB-500, and KPV were removed from FDA compounding Category 2 in April 2024 and are under PCAC review — access via US compounding pharmacies is uncertain or blocked.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching BPC-157 + TB-500 + GHK-Cu + KPV Stack.
- Injection-site reactions (4 injection sites if dosing separately, or 1 if using a pre-mixed blend)
- GI symptoms if KPV or BPC-157 taken orally
- Inflammatory markers (CRP, ESR) if using for chronic inflammation
- Subjective recovery metrics — pain, range of motion, wound healing speed
- Skin changes if using GHK-Cu topically (improved texture vs irritation)
- Any new or worsening symptoms — stacking peptides multiplies the unknowns
Frequently asked questions
What is BPC-157 + TB-500 + GHK-Cu + KPV Stack?
Multi-peptide combination stack for tissue repair, inflammation modulation, and regenerative support. This is a four-peptide combination stack that pairs BPC-157 and TB-500 (the core 'Wolverine stack' for tissue repair) with GHK-Cu (a copper peptide for collagen synthesis and skin health) and KPV (an anti-inflammatory tripeptide). Sold under names like KLOW Stack or Hyper Recovery Stack, it's marketed as a comprehensive healing protocol that hits every phase of tissue repair — from inflammation control through to collagen remodeling.
How is BPC-157 + TB-500 + GHK-Cu + KPV Stack administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of BPC-157 + TB-500 + GHK-Cu + KPV Stack?
Variable — Each component has its own pharmacokinetics — BPC-157 short (~hours), TB-500 longer (~days), GHK-Cu short, KPV short.
Is BPC-157 + TB-500 + GHK-Cu + KPV Stack approved for human use?
BPC-157 + TB-500 + GHK-Cu + KPV Stack is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for BPC-157 + TB-500 + GHK-Cu + KPV Stack?
Evidence tier: Weak / anecdotal. Zero published studies testing BPC-157, TB-500, GHK-Cu, and KPV together in the same experiment — all evidence is for individual components, not the stack (search results from PeptideWiki, PeptideDeck, and research vendor sites, 2025-2026).
What is commonly monitored when researching BPC-157 + TB-500 + GHK-Cu + KPV Stack?
Commonly tracked markers + signals: Injection-site reactions (4 injection sites if dosing separately, or 1 if using a pre-mixed blend), GI symptoms if KPV or BPC-157 taken orally, Inflammatory markers (CRP, ESR) if using for chronic inflammation, Subjective recovery metrics — pain, range of motion, wound healing speed, Skin changes if using GHK-Cu topically (improved texture vs irritation), Any new or worsening symptoms — stacking peptides multiplies the unknowns.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.